Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263135 | PMC |
| http://dx.doi.org/10.1097/QAI.0000000000002716 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Nivolumab can cause various immune-related adverse events; it rarely induces Vogt-Koyanagi-Harada-disease-like uveitis. Vogt-Koyanagi-Harada-disease is reported to be closely associated with human leukocyte antigen-DR4.
Case Presentation: A 68-year-old man with metastatic renal cancer underwent nephrectomy.
Non-tuberculous mycobacterial shoulder arthritis with acute exacerbation soon after initiation of immune checkpoint inhibitor: A case report.
J Infect Chemother
December 2024
Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan.
Immune checkpoint inhibitors (ICIs) have been approved for treating various cancers; however, they can cause immune-related adverse events. Generally, ICIs are not associated with an increased risk of infection, however, several reports demonstrated infections caused by non-tuberculous mycobacterium (NTM) during ICI therapy. Here, we report a case of NTM shoulder arthritis with acute exacerbation immediately after ICI initiation.
View Article and Find Full Text PDFCentral nervous system complications of immune checkpoint inhibitors: A comprehensive review.
Crit Rev Oncol Hematol
December 2024
Center for Clinical Investigation, INSERM U1434, Strasbourg University, 1 Avenue Molière, Strasbourg 67098, France; Neurology Department, Strasbourg University Hospitals, 1 Avenue Molière, Strasbourg 67098, France. Electronic address:
The ever-increasing use of immune checkpoint inhibitors (ICIs) has significantly improved cancer management, but at the cost of frequent immunologic side effects. Among them, neurologic immune-related adverse events (nirAEs) are less common but pose a challenge to clinicians due to their severity, heterogeneous nature and nonspecific clinical presentation, making diagnosis complex. The prognosis of these nirAEs, especially those related to the central nervous system (CNS), correlates with their rapid recognition and therapeutic management.
View Article and Find Full Text PDFDiaphragmatic Myopathy Associated with Dual Immune Checkpoint Inhibitors in a Patient with Renal Cell Carcinoma.
J Immunother Precis Oncol
November 2024
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Immune-related adverse events (irAEs) have become increasingly prevalent with immune checkpoint inhibitor (ICI) cancer treatment. We present a 79-year-old man with metastatic renal cell carcinoma who developed shortness of breath and hypercapnic respiratory insufficiency after his first cycle of nivolumab and ipilimumab. Laboratory data showed elevated creatinine kinase, troponins, and transaminases.
View Article and Find Full Text PDFMusculoskeletal ultrasound characteristics of checkpoint inhibitor-associated inflammatory arthritis.
Semin Arthritis Rheum
December 2024
Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Article Synopsis
- Cancer immunotherapy has significantly improved solid cancer treatment but can lead to immune-related side effects, including inflammatory arthritis, prompting the use of point-of-care musculoskeletal ultrasound (MSKUS) for diagnosis.* -
- In a study involving 55 patients with suspected musculoskeletal issues post-checkpoint inhibition therapy, it was found that 62% had definite inflammatory arthritis, with MSKUS revealing key features such as synovial thickening and hyperemia.* -
- MSKUS was particularly valuable, as it detected inflammatory signs in patients who showed no clinical symptoms, highlighting its effectiveness in diagnosing musculoskeletal immune-related adverse events.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!